<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v3.0 20080202//EN" "archivearticle3.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?release-delay 0|0 ?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Biol Chem</journal-id><journal-id journal-id-type="hwp">jbc</journal-id><journal-id journal-id-type="pmc">jbc</journal-id><journal-id journal-id-type="publisher-id">JBC</journal-id><journal-title-group><journal-title>The Journal of Biological Chemistry</journal-title></journal-title-group><issn pub-type="ppub">0021-9258</issn><issn pub-type="epub">1083-351X</issn><publisher><publisher-name>American Society for Biochemistry and Molecular Biology</publisher-name><publisher-loc>9650 Rockville Pike, Bethesda, MD 20814, U.S.A.</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">19383604</article-id><article-id pub-id-type="publisher-id">M109.004952</article-id><article-id pub-id-type="doi">10.1074/jbc.M109.004952</article-id><article-categories><subj-group subj-group-type="heading"><subject>Genomics, Proteomics, and Bioinformatics</subject></subj-group></article-categories><title-group><article-title>The Butyrylcholinesterase K Variant Confers Structurally Derived Risks for Alzheimer Pathology<xref ref-type="fn" rid="FN1">*</xref><xref ref-type="fn" rid="FN2"><sup><inline-graphic xlink:href="sbox.jpg"/></sup></xref><sup>&#x02666;</sup></article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Podoly</surname><given-names>Erez</given-names></name><xref ref-type="aff" rid="aff1"><sup>&#x02021;</sup></xref><xref ref-type="aff" rid="aff2"><sup>&#x000a7;</sup></xref><xref ref-type="other" rid="FN3"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Shalev</surname><given-names>Deborah E.</given-names></name><xref ref-type="aff" rid="aff2"><sup>&#x000a7;</sup></xref></contrib><contrib contrib-type="author"><name><surname>Shenhar-Tsarfaty</surname><given-names>Shani</given-names></name><xref ref-type="aff" rid="aff3"><sup>&#x000b6;</sup></xref></contrib><contrib contrib-type="author"><name><surname>Bennett</surname><given-names>Estelle R.</given-names></name><xref ref-type="aff" rid="aff1"><sup>&#x02021;</sup></xref></contrib><contrib contrib-type="author"><name><surname>Ben Assayag</surname><given-names>Einor</given-names></name><xref ref-type="aff" rid="aff3"><sup>&#x000b6;</sup></xref></contrib><contrib contrib-type="author"><name><surname>Wilgus</surname><given-names>Harvey</given-names></name><xref ref-type="aff" rid="aff4"><sup>&#x02016;</sup></xref></contrib><contrib contrib-type="author"><name><surname>Livnah</surname><given-names>Oded</given-names></name><xref ref-type="aff" rid="aff1"><sup>&#x02021;</sup></xref><xref ref-type="aff" rid="aff2"><sup>&#x000a7;</sup></xref></contrib><contrib contrib-type="author"><name><surname>Soreq</surname><given-names>Hermona</given-names></name><xref ref-type="aff" rid="aff1"><sup>&#x02021;</sup></xref><xref ref-type="corresp" rid="cor1"><sup>2</sup></xref></contrib><aff id="aff1">From <sup>&#x02021;</sup>The Alexander Silberman Life Sciences Institute and </aff><aff id="aff2"><sup>&#x000a7;</sup>The Wolfson Centre for Applied Structural Biology, Safra Campus Givat Ram, Hebrew University of Jerusalem, Jerusalem 91904, Israel, </aff><aff id="aff3">the <sup>&#x000b6;</sup>Department of Neurology, Sourasky Medical Center, Sackler Faculty of Medicine, Tel Aviv University, Tel-Aviv 69978, Israel, and </aff><aff id="aff4"><sup>&#x02016;</sup>PharmAthene Canada Inc., Montreal, Quebec QC H4S 2C8, Canada</aff></contrib-group><author-notes><corresp id="cor1"><sup>2</sup> To whom correspondence should be addressed: <addr-line>Dept. of Biological Chemistry, The Hebrew University of Jerusalem, Safra Campus, Givat Ram, Jerusalem 91904 Israel.</addr-line> Fax: <fax>972-2-652-0258</fax>; E-mail: <email>soreq@cc.huji.ac.il</email>.</corresp><fn id="FN3" fn-type="other"><label><sup>1</sup></label><p>An incumbent of the national Ph.D. Eshkol Fellowship.</p></fn></author-notes><pub-date pub-type="ppub"><day>19</day><month>6</month><year>2009</year></pub-date><pub-date pub-type="epub"><day>21</day><month>4</month><year>2009</year></pub-date><pub-date pub-type="pmc-release"><day>21</day><month>4</month><year>2009</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on the <pub-date pub-type="epub"/>. --><volume>284</volume><issue>25</issue><fpage>17170</fpage><lpage>17179</lpage><history><date date-type="received"><day>21</day><month>1</month><year>2009</year></date><date date-type="rev-recd"><day>6</day><month>4</month><year>2009</year></date></history><permissions><copyright-statement>&#x000a9; 2009 by The American Society for Biochemistry and Molecular Biology, Inc.</copyright-statement><license license-type="open-access"><license-p><italic>Author's Choice</italic>&#x02014;Final version full access.</license-p><license-p><ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/3.0/">Creative Commons Attribution Non-Commercial License</ext-link> applies to Author Choice Articles</license-p></license></permissions><self-uri xlink:title="pdf" xlink:type="simple" xlink:href="zbc02509017170.pdf"/><abstract><p>The K variant of butyrylcholinesterase (BChE-K, 20% incidence) is a long debated risk factor for Alzheimer disease (AD). The A539T substitution in BChE-K is located at the C terminus, which is essential both for BChE tetramerization and for its capacity to attenuate &#x003b2;-amyloid (A&#x003b2;) fibril formation. Here, we report that BChE-K is inherently unstable as compared with the &#x0201c;usual&#x0201d; BChE (BChE-U), resulting in reduced hydrolytic activity and predicting prolonged acetylcholine maintenance and protection from AD. A synthetic peptide derived from the C terminus of BChE-K (BSP-K), which displayed impaired intermolecular interactions, was less potent in suppressing A&#x003b2; oligomerization than its BSP-U counterpart. Correspondingly, highly purified recombinant human rBChE-U monomers suppressed &#x003b2;-amyloid fibril formation less effectively than dimers, which also protected cultured neuroblastoma cells from A&#x003b2; neurotoxicity. Dual activity structurally derived changes due to the A539T substitution can thus account for both neuroprotective characteristics caused by sustained acetylcholine levels and elevated AD risk due to inefficient interference with amyloidogenic processes.</p></abstract></article-meta></front><body><p>Butyrylcholinesterase (BChE),<xref ref-type="fn" rid="FN5"><sup>3</sup></xref> the secondary acetylcholine (ACh)-hydrolyzing enzyme, is associated with the neurofibrillary tangles and amyloid plaques characteristic of Alzheimer disease (AD) (<xref ref-type="bibr" rid="B1">1</xref>), which suggests that it functions as a potential AD modulator. BChE activity increases in the AD brain (<xref ref-type="bibr" rid="B2">2</xref><xref ref-type="bibr" rid="B3"/>&#x02013;<xref ref-type="bibr" rid="B4">4</xref>), where it co-localizes with &#x003b2;-amyloid (A&#x003b2;) fibrils (<xref ref-type="bibr" rid="B5">5</xref>, <xref ref-type="bibr" rid="B6">6</xref>). A&#x003b2; is a 39&#x02013;42-amino-acid amphiphilic peptide, derived from the transmembrane domain and extracellular region of the A&#x003b2; precursor protein (<xref ref-type="bibr" rid="B7">7</xref>). At high concentrations, A&#x003b2; acquires a &#x003b2;-sheet structure, becomes insoluble, and accumulates in neurotoxic oligomers and fibrils (<xref ref-type="bibr" rid="B8">8</xref>) to become the main constituent of plaques in the brain of AD patients. Recent hypotheses attribute causal roles in AD to presenilin (<xref ref-type="bibr" rid="B9">9</xref>), oxidative stress (<xref ref-type="bibr" rid="B10">10</xref>), metals (<xref ref-type="bibr" rid="B11">11</xref>), double hit origin (<xref ref-type="bibr" rid="B12">12</xref>), or mitochondrial damage (<xref ref-type="bibr" rid="B13">13</xref>). The alternative theories state that A&#x003b2; represents a bystander or even a protector rather than the causative factor of disease and that A&#x003b2; amyloidogenesis is secondary to other pathogenic events (<xref ref-type="bibr" rid="B14">14</xref>). Nevertheless, a wealth of evidence demonstrates a pivotal role for A&#x003b2; in the pathogenesis of AD, yielding the amyloid cascade hypothesis (<xref ref-type="bibr" rid="B15">15</xref>). According to this hypothesis, the pathological accumulation of A&#x003b2; in the brain leads to oxidative stress, neuronal destruction, and finally, the clinical syndrome of AD. It is within this context that we have studied the interactions of the Kalow variant (BChE-K) with A&#x003b2;.</p><p>The C terminus of BChE functions as a tetramerization domain (<xref ref-type="bibr" rid="B16">16</xref>, <xref ref-type="bibr" rid="B17">17</xref>) and is responsible for its quaternary organization. Four BChE monomers are held together by the aromatic interactions of seven highly conserved aromatic residues, termed the tryptophan amphiphilic tetramerization domain (WAT) (<xref ref-type="bibr" rid="B16">16</xref>, <xref ref-type="bibr" rid="B17">17</xref>). The WAT domain interacts with proline-rich attachment domains, either via proline-rich membrane anchor in brain neurons (<xref ref-type="bibr" rid="B18">18</xref>) or, in neuromuscular junctions, with cholinesterase-associated collagen Q (<xref ref-type="bibr" rid="B19">19</xref>). In the serum, BChE tetramerization is supported by an analogous 17-mer proline-rich peptide derived from lamellipodin (<xref ref-type="bibr" rid="B20">20</xref>).</p><p>Analyzing the quaternary organization of cholinesterases is a complicated task. To date, all biologically relevant crystal structures of cholinesterases have been truncated forms that lack the C terminus of the protein (<xref ref-type="bibr" rid="B21">21</xref>), apart from a more recent study of full-length BChE that yielded crystal packing, which did not allow C-terminal interactions among subunits and lacked electron densities in the C terminus region, indicating structural disorder Protein Data Bank (PDB) code <ext-link ext-link-type="pdb" xlink:href="1VZJ">1VZJ</ext-link> (<xref ref-type="bibr" rid="B22">22</xref>). Of note, the crystal structure of the homologous C terminus of tetrameric synaptic acetylcholinesterase (AChE-S) could only be determined based on synthetic peptides derived from the sequence of the AChE-S tail and stabilized with a proline-rich attachment domain (<xref ref-type="bibr" rid="B23">23</xref>).</p><p>In addition to the &#x0201c;usual&#x0201d; (BChE-U) form, BChE has nearly 40 genomic variants. The most common is BChE-K, with allelic frequencies of 0.13&#x02013;0.21. BChE-K includes a single nucleotide polymorphism at position 1699 (single nucleotide polymorphism data base (dbSNP) ID: rs1803274; alleles, A/G). This leads to an alanine-to-threonine substitution at position 539, 36 residues upstream to the C terminus of BChE (<xref ref-type="bibr" rid="B24">24</xref>), within the tetramerization domain that we previously found to attenuate amyloid fibril formation (<xref ref-type="bibr" rid="B25">25</xref>).</p><p>Ample evidence supports the importance of alanine-to-threonine substitutions and their relevance to amyloidogenic processes, protein stability, and quaternary organization (<ext-link ext-link-type="uri" xlink:href="http://www.jbc.org/cgi/content/full/M109.004952/DC1">supplemental Table ST1</ext-link>). Point mutations at the dimer interface of light chain immunoglobulins decrease their stability so that the A34T polymorphism in this protein leads to systemic amyloidosis (<xref ref-type="bibr" rid="B26">26</xref>). An A25T mutant of the tetrameric human protein Transthyretin (TTR), associated with central nervous system amyloidosis, is prone to aggregation and exhibits drastically reduced tertiary and quaternary structural stabilities (<xref ref-type="bibr" rid="B27">27</xref>). The thermodynamic stability profile of the A25T TTR mutant shows that both monomers and tetramers of this variant are highly destabilized. In addition, A25T TTR tetramers dissociate very rapidly (about 1200-fold faster than the dissociation of wild-type TTR), reflecting a high degree of kinetic destabilization of their quaternary structure. These factors together probably contribute to the high propensity of A25T TTR to aggregate <italic>in vitro</italic>.</p><p>The capacity of serum BChE-K to hydrolyze butyrylthiocholine was reported to be reduced by 30% relative to BChE-U, for yet unclear reasons (<xref ref-type="bibr" rid="B24">24</xref>). The reduced hydrolytic activity of BChE-K predicts that BChE-K carriers would potentially sustain improved cholinergic transmission as compared with BChE-U carriers and has been shown to correlate with preserved performance of attention and reduced rates of cognitive decline (<xref ref-type="bibr" rid="B28">28</xref>). However, BChE-K carriers are refractory to cholinesterase inhibitor therapy, the current leading treatment of AD (<xref ref-type="bibr" rid="B29">29</xref>). This raised the question whether BChE-K functions as an AD risk or protection factor. Genotype studies are controversial, with some showing increased risk of AD for homozygote BChE-K carriers (<italic>e.g.</italic> Ref. <xref ref-type="bibr" rid="B30">30</xref>), whereas others suggest a protective effect (<italic>e.g.</italic> Ref. <xref ref-type="bibr" rid="B31">31</xref>). A recent meta-analysis concluded that on average, BChE-K is neither a risk factor nor a protection factor for AD (<xref ref-type="bibr" rid="B32">32</xref>). Based on our previous findings of the arrest of A&#x003b2; fibril formation by BChE and considering the accumulation of monomeric BChE in the most severe AD cases (<xref ref-type="bibr" rid="B33">33</xref>), we used a variety of chemical techniques to study the effect of the A539T substitution on BChE stability and tetramerization on the one hand and on its potency in attenuating A&#x003b2; oligomerization and fibril formation on the other.</p><sec sec-type="methods"><title>EXPERIMENTAL PROCEDURES</title><sec><title/><sec><title/><sec sec-type="subjects"><title>Subjects</title><p>321 (184 males, 137 female) healthy individuals (mean &#x000b1; S.D. age: 65.99 &#x000b1; 11.11 years) from various out-patient clinics of the Tel-Aviv Sourasky Medical Center were enrolled during the period from February 2001 to September 2004, as described (<xref ref-type="bibr" rid="B34">34</xref>). Written informed consent, approved by the local ethics committee (consent form 00-116), was obtained from all participants.</p></sec><sec><title>Gene Polymorphism Analysis</title><p>Genomic DNA was extracted from nucleated blood cells. For single nucleotide polymorphism analysis, a 214-bp PCR product was amplified using the forward primer 5&#x02032;-CTGTACTGTGTAGTTAGAGAAAATGGC-3&#x02032; (nucleotide &#x02212;105 to &#x02212;79 upstream to the intron 3/exon 4 boundary) and the reverse primer 5&#x02032;-CTTTCTTTCTTGCTAGTGTAATCG-3&#x02032; (nucleotides 1709-1686). A fluorescein-labeled anchor probe (5&#x02032;-CCAGCGATGGAATCCTGCTTTCC-3&#x02032;-FLU (fluorescein), nucleotides 1628&#x02013;50) and a one base apart LC-Red-640-labeled detection probe (5&#x02032;-CTCCCATTCTGCTTCATCAATATT-3&#x02032;-PHO (phosphate), nucleotides 1603-26) were used as reported previously (<xref ref-type="bibr" rid="B35">35</xref>).</p></sec><sec><title>Serum Cholinesterase Analysis</title><p>Acetylthiocholine (ATCh) hydrolytic activities were assessed in a microtiter plate assay as described, with or without the selective BChE inhibitor iso-OMPA (tetra(monoisopropyl)pyrophosphorotetramide) (<xref ref-type="bibr" rid="B36">36</xref>). Calculated BChE ATCh hydrolytic activity was defined as the total serum ability to hydrolyze ATCh after subtraction of AChE hydrolytic activity. For stability tests, serum-derived samples of genotyped KK, UK, and UU carriers, diluted 1:10 in saline, were incubated overnight in 0&#x02013;2 <sc>m</sc> urea at 37 &#x000b0;C and electrophoretically separated (2 h, 4 &#x000b0;C) in 6% non-denaturing polyacrylamide gels. This was followed by activity staining with 3.0 m<sc>m</sc> copper sulfate, 0.5 m<sc>m</sc> potassium ferricyanide, 10 m<sc>m</sc> sodium citrate, 1.6 m<sc>m</sc><italic>S</italic>-butyrylthiocholine iodide, and 65 m<sc>m</sc> phosphate buffer, pH 6.0, at room temperature (<xref ref-type="bibr" rid="B37">37</xref>).</p></sec><sec><title>Statistical Analysis</title><p>Continuous data were summarized and displayed as mean &#x000b1; S.D. Distributions of calculated BChE activities were assessed by the Kolmogorov-Smirnov Normality test. The difference between genotypes of mean calculated activities was evaluated using Student's <italic>t</italic> test; <italic>p</italic> &#x0003c; 0.05 was considered statistically significant. SPSS for Windows (version 15.0, SPSS Inc.) software was used to carry out all statistical analyses.</p></sec><sec><title>Peptides</title><p>Peptides used were: A&#x003b2;<sub>1&#x02013;40</sub>, (Sigma, Jerusalem, Israel), BSP-U and BSP-K, derived from the C-terminal sequences of human BChE (EC 3.1.1.8.) variants (U, GNIDEAEWEWKAGFHRWNNYMMDWKNQFNDYT; K, A6T), and the 17-mer poly-<sc>l</sc>-proline (PolyP) sequence (PPPPPPPPPPPPPPPLP), derived from lamellipodin, which promotes the assembly of BChE into tetramers (<xref ref-type="bibr" rid="B20">20</xref>) (GenScript Corp., Piscataway, NJ). All peptides were purified to &#x0003e;90%, as validated by mass spectrometry analyses.</p></sec><sec><title>Surface Plasmon Resonance</title><p>The ProteOn<sup>TM</sup> XPR36 protein interaction array system (Bio-Rad, Haifa, Israel) was used to study the interaction of a recombinant full-length BChE (rBChE-U) and the peptides BSP-U and BSP-K, with a polyclonal antibody raised against rBChE-U (<xref ref-type="bibr" rid="B38">38</xref>). The protein and peptides were immobilized on GLC chips (Bio-Rad) using standard amine coupling. Arbitrary units (resonance unit) values of binding to the chip were 6000, 900, and 600, respectively. The antibody, as analyte, was diluted serially in phosphate-buffered saline containing 0.005% Tween 20 and injected at five concentrations (3.12&#x02013;50 &#x003bc;g/ml). All interactions were carried out at 25 &#x000b0;C. Immobilized IgG was used as a reference for background subtraction.</p></sec><sec><title>NMR-derived Solution Analysis of BSP Peptides</title><p>Peptides were dissolved in 60% <italic>d<sub>6</sub></italic>-DMSO (Aldrich) in double distilled water with 0.03 weight percent NaN<sub>3</sub> and measured at 29 &#x000b0;C. BSP samples were measured alone and with PolyP at a 4:1 molar ratio (verified by relative peak-ratios in NMR spectra). The pH was titrated to 5.10 &#x000b1; 0.05 for all samples. NMR experiments were performed on a Bruker Avance 600 MHz DMX spectrometer operating at the proton frequency of 600.13 MHz, using a 5-mm selective probe equipped with a self-shielded xyz-gradient coil. The transmitter frequency was set on the hydrogen-deuterium exchange in water signal, which was calibrated at 4.735 ppm. total correlation spectroscopy, using the MLEV-17 pulse scheme for the spin lock (<xref ref-type="bibr" rid="B39">39</xref>), and nuclear Overhauser effect spectroscopy (<xref ref-type="bibr" rid="B40">40</xref>) experiments were acquired under identical conditions for all samples, using gradients for water saturation. The nuclear Overhauser effect spectroscopy experiments were acquired with a mixing time of 200 ms.</p><p>Spectra were processed and analyzed with the XWINNMR (Bruker Analytische Messtechnik GmbH) and SPARKY3 software.<xref ref-type="other" rid="FN6"><sup>4</sup></xref> Zero filling in the F1 dimension and data apodization with a shifted squared sine bell window function in both dimensions were applied prior to Fourier transformation. The baseline was further corrected in the F2 dimension with a quadratic polynomial function. Resonance assignment followed the sequential assignment methodology developed by W&#x000fc;thrich (<xref ref-type="bibr" rid="B41">41</xref>).</p></sec><sec><title>A&#x003b2; Oligomerization</title><p>Oxidative photo-induced cross-linking of unmodified proteins (<xref ref-type="bibr" rid="B42">42</xref>) was used to study the effect of BSP peptides on A&#x003b2; oligomerization. A&#x003b2; was preincubated in hexafluoroisopropanol (Acros Organics, Geel, Belgium), lyophilized and redissolved in double distilled water to a final concentration of 100 &#x003bc;<sc>m</sc>. A&#x003b2; was incubated alone or in the presence of 1 &#x003bc;<sc>m</sc> protein or peptides over 24 h at room temperature. Aliquots were removed at 0, 4, 7, 8, and 22 h and centrifuged (30 min, 14,000 rpm). Soluble fractions were treated as described previously (<xref ref-type="bibr" rid="B43">43</xref>). Thioflavine T and bis-ANS fluorescence measurements and transmission electron microscopy were done as described (<xref ref-type="bibr" rid="B25">25</xref>, <xref ref-type="bibr" rid="B43">43</xref>).</p></sec><sec><title>Circular Dichroism Measurements</title><p>Direct CD spectra were recorded using a CD Jasco J-810 spectropolarimeter (Easton, MD) in 1-mm path length quartz cuvettes, Hellma 100-QS (Hellma GmbH &#x00026; Co. KG, M&#x000fc;lheim/Baden, Germany). Recordings were at 0.1-nm intervals in a spectral range of 185&#x02013;260 nm. The CD spectra were computationally deconvoluted, using the K2D analysis program (<xref ref-type="bibr" rid="B44">44</xref>). The concentration of BSP peptides was below the level of detection so that the spectra measured changes in A&#x003b2; only.</p></sec><sec><title>Cell Culture</title><p>Human neuroblastoma SH-SY5Y cells (ATCC, Manassas, VA) were grown in a 1:1 mixture of minimal essential medium (Sigma-Aldrich, Rehovot, Israel) and Ham's modified medium F-12 (Sigma), with 10% fetal bovine serum (Biological Industries, Beit-Haemek, Israel). Cells were plated in 24-well plates (Nunc, Roskilde, Denmark) at 10<sup>5</sup> cells/well in 500 &#x003bc;l of medium and allowed to attach overnight. A&#x003b2; was preincubated for 4 h, diluted 1:10 (final volume 500 &#x003bc;l) with phenol red-free RPMI 1640 (Sigma) containing 10% serum, and added to the cells. Cell viability was determined using lactate dehydrogenase (LDH) release assays (<xref ref-type="bibr" rid="B45">45</xref>) as described (<xref ref-type="bibr" rid="B38">38</xref>).</p></sec></sec></sec></sec><sec sec-type="results"><title>RESULTS</title><sec><title/><sec><title/><sec><title>BChE-K Shows Reduced Stability and Hydrolytic Activity</title><p>The BChE genotype (<xref ref-type="fig" rid="F1">Fig. 1</xref>, <italic>A</italic> and <italic>B</italic>) was determined using nucleated blood cell DNA from apparently healthy volunteers who also donated serum for hydrolytic activity measurements. The observed genotype distribution included 72.0% UU, 23.2% UK, and 4.4% KK variants, consistent with the Hardy-Weinberg equilibrium. The corresponding mean calculated ATCh hydrolytic activities of serum BChE from these subjects were 1103.31 &#x000b1; 219.34, 1031.16 &#x000b1; 198.56, and 949.05 &#x000b1; 203.47 (<italic>p</italic> = 0.011) (<xref ref-type="fig" rid="F1">Fig. 1</xref><italic>C</italic>). The decline in ATCh hydrolytic activity from heterozygous to homozygous carriers indicated gene dose dependence.</p><fig id="F1" position="float"><label>FIGURE 1.</label><caption><p><bold>The <italic>BChE</italic> gene and its usual U and K variant protein products.</bold><italic>A</italic>, BChE location on chromosome 3q26.1-q26.2 and its gene structure (<xref ref-type="bibr" rid="B56">56</xref>). <italic>B</italic>, the C-terminal DNA and amino acid sequences of BChE-U and -K. The predicted secondary structure of the amino acid substitution (enlarged) is shown above the sequences. <italic>C</italic>, histograms of measured BChE activity in apparently healthy carriers of the UU, UK, and KK genotypes. Units are nmol of acetylthiocholine hydrolyzed/min/ml serum.</p></caption><graphic xlink:href="zbc0290979660001"/></fig><p>The location of the A539T substitution in the C terminus, which is distant from the hydrolytic site of the enzyme, suggested that its impaired stability caused the reduced activity. To challenge this prediction, the inherent stability of BChE-U and BChE-K was compared by incubating serum samples from genotyped subjects in increasing concentrations of urea followed by native gel electrophoresis and activity staining (<xref ref-type="fig" rid="F2">Fig. 2</xref><italic>A</italic>). Both BChE-U and BChE-K are enzymatically active tetramers; however, the enzymatic activity of BChE-K tetramers was greatly reduced following incubation in 1 <sc>m</sc> urea, unlike BChE-U, which was resistant to this treatment. This suggested that the hydrolytic activity was rapidly lost once BChE-K tetramers disassemble.</p><fig id="F2" position="float"><label>FIGURE 2.</label><caption><p><bold>BChE and derived peptides differ in stability and antibody recognition.</bold><italic>A</italic>, native gel subjected to activity staining of homozygous BChE-U and -K serum samples following incubation in the noted molar concentrations of urea. <italic>B</italic>, surface plasmon resonance analyses. Polyclonal anti-rBChE-U antibodies in the noted concentrations were injected against immobilized rBChE-U, BSP-U, and BSP-K. Signals are dose-dependent. Note the 10-fold resonance unit scale difference between rBChE-U and BSP-U signals and the lack of detectable interaction with BSP-K. <italic>C</italic> and <italic>D</italic>, positive surface plasmon resonance response of BSP-U but neither BSP-K nor IgG. Note the exceedingly low response scale despite adding 6000 resonance units (<italic>RU</italic>) of IgG, attesting to the specificity of the observed response with the anti-BChE antibodies (<italic>Ab</italic>).</p></caption><graphic xlink:href="zbc0290979660002"/></fig></sec><sec><title>BSP Peptides Show NMR Spectral Differences</title><p>We investigated the structural origin for the instability of BChE-K by analyzing the corresponding 32-residue synthetic peptides, BSP-K and BSP-U, for their interaction with a polyclonal rabbit antibody elicited toward intact rBChE-U (<xref ref-type="bibr" rid="B46">46</xref>). Surface plasmon resonance analysis demonstrated a dose-dependent interaction of anti-rBChE-U antibodies with rBChE-U and BSP-U (albeit less profoundly) but not with BSP-K (<xref ref-type="fig" rid="F2">Fig. 2</xref>, <italic>B</italic> and <italic>C</italic>). Immunoglobulin G, which does not bind to the antibody against rBChE-U (<xref ref-type="fig" rid="F2">Fig. 2</xref><italic>D</italic>) served as an immobilized control employed as a subtractable &#x0201c;baseline&#x0201d; in all cases. Additionally, other injected proteins (<italic>e.g.</italic> RACK1) did not bind rBChE or the two peptides (data not shown).These results supported the concept of structural differences between these two peptides and suggested that distinct tetramerization capacities are involved. Interactions of BSP peptides were studied by incubating them with the synthetic PolyP peptide, which facilitates BChE tetramerization (<xref ref-type="bibr" rid="B20">20</xref>). NMR was used to follow both BSP peptides interactions with PolyP by tracking chemical shift deviations in the amide-aliphatic interactions (fingerprint region). Because PolyP fortunately has no amide protons (apart from one leucine), it does not appear in the fingerprint region of the BSP spectra.</p><p>The spectrum of BSP-U was assigned based on total correlation spectroscopy and nuclear Overhauser effect spectroscopy spectra acquired under identical conditions and was the basis for assignments of both BSP peptides with 4:1 ratios of peptide to PolyP (see <ext-link ext-link-type="uri" xlink:href="http://www.jbc.org/cgi/content/full/M109.004952/DC1">supplemental Figs. SF1&#x02013;4</ext-link>: <ext-link ext-link-type="uri" xlink:href="http://www.jbc.org/cgi/content/full/M109.004952/DC1">supplemental Fig. 1</ext-link>, BSP-U; <ext-link ext-link-type="uri" xlink:href="http://www.jbc.org/cgi/content/full/M109.004952/DC1">supplemental Fig. 2</ext-link>, BSP-U+PolyP; <ext-link ext-link-type="uri" xlink:href="http://www.jbc.org/cgi/content/full/M109.004952/DC1">supplemental Fig. 3</ext-link>, BSP-K; <ext-link ext-link-type="uri" xlink:href="http://www.jbc.org/cgi/content/full/M109.004952/DC1">supplemental Fig. 4</ext-link>, BSP-K<sup>+</sup>PolyP). Deviations of amide chemical shifts of each peptide in interaction with PolyP <italic>versus</italic> the free state are summarized in <xref ref-type="fig" rid="F3">Fig. 3</xref>.</p><fig id="F3" position="float"><label>FIGURE 3.</label><caption><p><bold>PolyP-induced NMR chemical shift deviations.</bold> NMR-measured chemical shift differences between spectra of BSP-U and -K bound and non-bound to PolyP (shown as a <italic>central thread</italic> in the structure) are displayed. <italic>Right</italic>, location of residues that showed significant chemical shifts on the BSP structure (built according to PDB structure <ext-link ext-link-type="pdb" xlink:href="1VZJ">1VZJ</ext-link>) are colored in <italic>pink</italic>. Residues near the kink of the helix at Gly-546 (in <italic>blue</italic>) were significantly shifted in both BSP peptides.</p></caption><graphic xlink:href="zbc0290979660003"/></fig><p>Upon adding PolyP, BSP-U showed mainly upfield chemical shift deviations, suggesting that the amide protons are more shielded in this variant when interacting with PolyP. The amide protons of BSP-K showed the opposite, except for residues His-15 and Arg-16, which were shielded, and Asn-2, Trp-24, and Tyr-31, which were deshielded in both peptides. The distinct interactions observed for these peptides with PolyP suggested inherent differences between their tetramerization potency, compatible with the reduced stability of BChE-K as compared with BChE-U.</p></sec><sec><title>rBChE-U Monomers Suppress Fibril Formation Less Effectively than Recombinant Dimers or Native BChE Tetramers</title><p>The C-terminal domains of both BChE dimers and monomers are relatively exposed to the surrounding environment, as modeled based on the tetrameric structure of AChE-S (<xref ref-type="fig" rid="F4">Fig. 4</xref><italic>A</italic>). Separate fractions of BChE dimers and monomers were used to compare the effects caused by these C termini. rBChE-U production in the milk of transgenic goats yielded primarily dimeric protein, with &#x0223c;10% monomeric fraction, as shown by mass spectrometry (<xref ref-type="bibr" rid="B46">46</xref>) (<xref ref-type="fig" rid="F4">Fig. 4</xref><italic>B</italic>). Column chromatography was used to separate monomers from dimers. ThT fluorescence measurements showed that isolated fractions of highly purified rBChE-U monomers and dimers both attenuated fibril formation at a molar ratio of 1:100 to A&#x003b2;. However, monomeric and dimeric rBChE-U showed different durations of the lag and growth phases in the fibril formation process (<xref ref-type="fig" rid="F4">Fig. 4</xref><italic>C</italic>). Dimeric rBChE-U attenuated A&#x003b2; fibril formation more than the monomeric BChE and presented a longer lag time and 20% less fluorescent signal at the plateau (<xref ref-type="fig" rid="F4">Fig. 4</xref><italic>C</italic> and <italic>inset</italic>). Furthermore, calculating the rate of fibril formation revealed that recombinant BChE dimers (<xref ref-type="fig" rid="F4">Fig. 4</xref><italic>D</italic>), and yet more so, native BChE from human serum (<xref ref-type="fig" rid="F4">Fig. 4</xref><italic>E</italic>) attenuate this process, suggesting direct association of this rate with the number of enzyme subunits. Inversely, a bis-ANS response curve to rBChE interaction with A&#x003b2; showed an apparently similar time scale and sustained fluorescence signal, unlike the reduced signal in the thioflavin T tests (<xref ref-type="fig" rid="F4">Fig. 4</xref><italic>F</italic>), both supporting our working hypothesis.</p><fig id="F4" position="float"><label>FIGURE 4.</label><caption><p><bold>rBChE-U dimers attenuate A&#x003b2; fibril formation more effectively than monomers.</bold><italic>A</italic>, initial dimer and monomer content in rBChE-U preparation. <italic>B</italic>, modeled BChE-U monomers and dimers built according to PDB structure <ext-link ext-link-type="pdb" xlink:href="1EEAY">1EEAY</ext-link> of the tetrameric structure of AChE-S. <italic>AU</italic>, arbitrary units. <italic>C</italic>, ThT fluorescence demonstrating that highly purified dimers of rBChE-U suppressed A&#x003b2; fibril formation more efficiently than monomeric rBChE-U. <italic>Inset</italic>, percentage of attenuated A&#x003b2; fibril formation elicited by monomers (<italic>m</italic>) and dimers (<italic>d</italic>). <italic>D</italic> and <italic>E</italic>, rates of fluorescence changes demonstrating the difference in the capacity for attenuating fibril formation by human recombinant rBChE dimers (<italic>d</italic>) or serum-derived tetramers (<italic>t</italic>). <italic>F</italic>, bis-ANS kinetics demonstrating an apparently similar time scale and sustained fluorescence signal in the presence of bis-ANS as compared with the suppressed signal with ThT, both supporting our working hypothesis.</p></caption><graphic xlink:href="zbc0290979660004"/></fig><p>The distinct structural features of BSP-K could potentially impair its ability to modulate A&#x003b2; conversion to &#x003b2;-sheet conformation. This was assessed by incubating A&#x003b2; alone or with BSP peptides and following the CD spectrum for 24 h. Deconvoluted spectra of A&#x003b2; samples incubated alone showed a gradual increase in the content of &#x003b2;-sheets, from 26 to 50% within 2.5 h. In contrast, adding rBChE-U or BSP peptides to A&#x003b2; accelerated the increase in &#x003b2;-sheet content, which reached an apparent plateau within seconds (50 s, to 48%) (<xref ref-type="fig" rid="F5">Fig. 5</xref>).</p><fig id="F5" position="float"><label>FIGURE 5.</label><caption><p><bold>CD evidence for BChE-accelerated conversion to &#x003b2;-sheet conformation.</bold> CD deconvoluted spectra demonstrate a rapid increase in &#x003b2;-sheet content (<italic>upper plot</italic>) and rapid decrease in helical content (<italic>lower plot</italic>) with the addition of rBChE-U, BSP-U, and BSP-K, as compared with the increase in &#x003b2;-sheet content seen with A&#x003b2; alone.</p></caption><graphic xlink:href="zbc0290979660005"/></fig></sec><sec><title>BSP-K Attenuates A&#x003b2; Oligomerization Less Effectively than BSP-U</title><p>Further studies of A&#x003b2; oligomerization involved cross-linking of A&#x003b2; in the presence or absence of BSP-U or BSP-K and separation of the soluble fractions by SDS-PAGE (<xref ref-type="fig" rid="F6">Fig. 6</xref>). A&#x003b2; alone precipitated rapidly, within 4 h. Both BSP peptides prolonged the time A&#x003b2; oligomers remained in solution, but BSP-U prolonged the persistence of amyloid oligomers in solution more effectively than BSP-K; after 8 h of incubation, no oligomeric forms of A&#x003b2; remained in the soluble phase in the presence of BSP-K, whereas in the presence of BSP-U, they lasted nearly 22 h. This supports the view that BSP-K is less capable of interacting both with PolyP and with A&#x003b2; than BSP-U.</p><fig id="F6" position="float"><label>FIGURE 6.</label><caption><p><bold>BSP-K sustains less cross-linked A&#x003b2; oligomers in solution than BSP-U.</bold><italic>A</italic>, 16% Tris-Tricine gel demonstrating BSP peptide interference with oligomerization of A&#x003b2;. <italic>MW</italic>, molecular weight markers; <italic>no CL</italic>, no cross-linking. <italic>B</italic>, the cross-linking reaction. <italic>Prot</italic>, protein. <italic>C</italic>, quantification of A&#x003b2; dimers and trimers in solution, in the presence of BSP-K and BSP-U.</p></caption><graphic xlink:href="zbc0290979660006"/></fig></sec><sec><title>rBChE-U Attenuates A&#x003b2; Fibril Formation and Induces Fibril Disassembly</title><p>Transmission electron microscopy (TEM) was used to quantify longer and more developed A&#x003b2; fibrils, formed in the presence or absence of rBChE-U and BSP peptides. Following 48 h of incubation, A&#x003b2; alone formed mostly 50&#x02013;60-nm-long fibrils, with some fibrils reaching up to 300 nm. In the presence of either of the BSP peptides, however, the majority of A&#x003b2; fibrils were 20&#x02013;30-nm long with none longer than 120 nm. In the presence of rBChE-U, a dramatic reduction in the formation of fibrils of all length groups was seen, as compared with A&#x003b2; incubated alone or with BSP peptides (<xref ref-type="fig" rid="F7">Fig. 7</xref><italic>A</italic>).</p><fig id="F7" position="float"><label>FIGURE 7.</label><caption><p><bold>rBChE-U attenuates fibril formation more than BSP peptides and induces fibril disassembly.</bold><italic>A</italic>, computer-processed TEM photomicrographs following 24-h incubations of A&#x003b2; alone or with BSP-U, BSP-K, or rBChE-U. <italic>B</italic>, fibrils were clustered into groups according to their length. Note that both BSP peptides shifted the A&#x003b2; fibrils from relatively long to numerous short fibrils, whereas rBChE-U suppressed the formation of fibrils of all length groups. <italic>C</italic> and <italic>D</italic>, A&#x003b2; alone or with rBChE-U added after different incubation times (shown by <italic>arrows</italic>). Plots present the fibril number or branches <italic>versus</italic> fibril length. Note the apparent disassembly of preformed fibrils. <italic>E</italic>, ThT fluorescence curves for the BSP-U and the BSP-K peptides. Note that BSP-U, but not BSP-K, was capable of repressing the ThT increment induced by A&#x003b2;. <italic>FU</italic>, fluorescence units.</p></caption><graphic xlink:href="zbc0290979660007"/></fig><p>Kinetics of TEM showed a pronounced decrease over time both in the number and in the degree of branching of the fibrils in the presence of the peptides relative to incubation of A&#x003b2; alone. Adding rBChE-U at any time after initiation substantially further reduced the number of fibrils in a manner dependent on the duration of rBChE-U incubation for all fibril length fractions. Also, adding rBChE-U decreased the extent of branching. <xref ref-type="fig" rid="F7">Fig. 7</xref>, <italic>A&#x02013;D</italic>, present these analyses and the corresponding quantifications, demonstrating active disassembly of fibrils by rBChE-U. Of note, ThT fluorescence measurements showed suppressed increment in the presence of BSP-U, but not BSP-K (<xref ref-type="fig" rid="F7">Fig. 7</xref><italic>E</italic>), demonstrating a principal difference between these two peptides.</p></sec><sec><title>BSP Peptides Are Poor Neuroprotectors as Compared with rBChE-U</title><p>Cytotoxicity of A&#x003b2; has been attributed to low molecular weight oligomers (<xref ref-type="bibr" rid="B47">47</xref>, <xref ref-type="bibr" rid="B48">48</xref>). Therefore, A&#x003b2; cytotoxicity and the cytoprotection provided by BSP peptides and rBChE-U was tested on cultured human neuroblastoma SH-SY5Y cells. The cells were incubated alone, in the presence of A&#x003b2; and in the presence of A&#x003b2; with BSP peptides or rBChE-U. After 72 h, an LDH release assay for cell viability showed a 26% increase in LDH release from A&#x003b2;-treated cells as compared with controls. rBChE-U prevented 85 &#x000b1; 8% of this A&#x003b2;-induced LDH increase, indicating that it protects the cells from the A&#x003b2;-dependent toxicity. The BSP peptides yielded only small, variable (10&#x02013;17%) changes in LDH release, suggesting that they can only function to attenuate A&#x003b2; fibril formation as an integral part of the intact BChE protein.</p></sec></sec></sec></sec><sec sec-type="discussion"><title>DISCUSSION</title><p>Various chemical and biological approaches were combined to explore the role of the BChE-K variant in A&#x003b2; accumulation, which characterizes AD pathophysiology. Our findings attribute many of the features observed for BChE-K carriers in AD to structural origins. We found BChE-K to be inherently unstable as compared with BChE-U, which may induce elevated ACh levels in its carriers, thereby delaying AD onset. However, BChE-K was considerably less effective in attenuating the accumulation of A&#x003b2; fibrils than BChE-U. Although bearing in mind the alternative hypotheses for the role played by A&#x003b2; in AD, our findings suggest that BChE-K may pose either a risk or a protective factor in AD, in a context-dependent manner affected by other variables. It is conceivable that distinct population studies reflect these variables so that the null differences observed in the meta-analysis are less meaningful than the different population studies. Our findings attribute the association between BChE-K and AD progression to a structural origin, with dual activity: impaired stability and quaternary organization of BChE-K as compared with BChE-U and the consequently suppressed hydrolytic activity, counterbalanced by aberrant interactions with A&#x003b2;. This statement is supported by several considerations, as listed below.</p><p>The genetic implications of BChE-K in AD progression were studied comprehensively (<ext-link ext-link-type="uri" xlink:href="http://www.jbc.org/cgi/content/full/M109.004952/DC1">supplemental Table ST2</ext-link>), but the location of the A539T polymorphism within the tetramerization domain of BChE (<xref ref-type="bibr" rid="B16">16</xref>, <xref ref-type="bibr" rid="B17">17</xref>) has not been considered. Our current findings suggest that the BChE-K C-terminal substitution impairs both its stability and its intersubunit interactions. This is supported by findings where tetrameric serum BChE is thermostable, demonstrating that monomeric BChE loses hydrolytic activity within 10 min when incubated at 48 &#x000b0;C (<xref ref-type="bibr" rid="B49">49</xref>).</p><p>NMR detected chemical shift differences between BSP peptides upon adding PolyP. Nine residues in three regions of BSP-U showed chemical shift deviations (&#x00394;&#x003b4; &#x02265; 0.02), as compared with only two BSP-K residues. Also, the changes observed in the BSP-U spectra upon binding PolyP were larger than those in the BSP-K spectra, indicating that PolyP induces greater organization in BSP-U. Changes in NMR chemical shift largely indicate those residues that undergo structural changes upon binding (<italic>e.g.</italic> Ref. <xref ref-type="bibr" rid="B50">50</xref>). The distribution of BSP regions whose adjacent chemical environment changed, including the middle region and both termini, may indicate a change in the relative tilt of the helices or a motion in the hinge of the helix (at Gly-546/Gly-13) due to rearrangement of the kink. Such motion may result from local helix disruption due to the A539T mutation; according to the Chou-Fasman parameters (<xref ref-type="bibr" rid="B51">51</xref>), alanine is one of the strongest helix stabilizers (helix propensity: 1.42), whereas threonine is one of the strongest &#x003b2;-sheet formers (&#x003b2;-sheet propensity: 1.19). One possible explanation of our findings is that threonine may slightly disrupt the helix or the amphiphilic distribution. The preference of threonine to form &#x003b2;-sheets is crucial in the context of amyloidogenic processes as all amyloid fibrils share a common cross-&#x003b2;-sheet structure. Another example of a disrupted helix originating from an alanine-to-threonine substitution is the solid-state NMR study that showed that the familial Parkinson disease-associated mutation A53T, which occurs in the N terminus of the amphiphilic helical &#x003b1;-synuclein, is more prone to forming &#x003b2;-structures than wild-type &#x003b1;-synuclein (<xref ref-type="bibr" rid="B52">52</xref>).</p><p>In BChE-K, the disrupted helix would likely be further destabilized by hydrogen bonding between Thr-539 and Glu-543, three amino acids away. Local unwinding of the helix could lead to loss of the ability of the adjacent pivotal tryptophan (Trp-541), which we previously demonstrated disrupts this amphiphilic helix, to attenuate A&#x003b2; fibril formation (<xref ref-type="bibr" rid="B25">25</xref>). Trp-541 contributes to structural interactions only when it is located at the polar face of an amphiphilic helix; if the helix becomes twisted or distorted, Trp-541 is no longer at the polar face, and the entire helix may cease to be amphiphilic.</p><p>Various A&#x003b2; aggregation pathways may exist simultaneously, and distinct inhibitors may affect only some of these. For instance, if oligomers are essential intermediates on the pathway to fibril formation, inhibitors that block oligomer formation would ultimately block fibril formation as well. Alternatively, if fibrils and oligomers represent distinct aggregation pathways, some inhibitors might block oligomerization but not fibril formation and <italic>vice versa</italic>. We followed A&#x003b2; oligomerization by cross-linking, and we followed fibril formation by TEM. In both approaches, rBChE-U and BSP peptides attenuated both oligomer and fibril formation, albeit with different efficiencies. This tentatively implies that under the experimental conditions employed, oligomers are fibril intermediates. One possible explanation of the observed attenuation effects is that both rBChE-U and the BSP peptides can induce a shift of A&#x003b2; accumulation toward a stabilized A&#x003b2; oligomer, as large as 100-mer, if judged by the 1:100 molar ratio of effective inhibition (<xref ref-type="fig" rid="F8">Fig. 8</xref>).</p><fig id="F8" position="float"><label>FIGURE 8.</label><caption><p><bold>BChE-induced changes in the A&#x003b2; accumulation process.</bold> The A&#x003b2; aggregation pathway involves a set of mutually dependent reactions in complex equilibria (monomer &#x021c6; dimer &#x021c6; oligomer &#x021c6; fibril). The transition from helical structure to &#x003b2;-sheet conformation was studied by CD, oligomerization was followed by cross-linking, and fibril formation was tracked by ThT fluorescence and TEM. These reactions along the A&#x003b2; aggregation pathway are differentially affected by rBChE-U, BSP-U, and BSP-K.</p></caption><graphic xlink:href="zbc0290979660008"/></fig><p>The amyloid hypothesis postulates that increased A&#x003b2; production and deposition plays a key role in triggering neuronal dysfunction and death in AD (<xref ref-type="bibr" rid="B15">15</xref>, <xref ref-type="bibr" rid="B53">53</xref>). Many argue that the toxicity of A&#x003b2; lies in its soluble oligomeric intermediates (<xref ref-type="bibr" rid="B47">47</xref>, <xref ref-type="bibr" rid="B48">48</xref>) rather than the insoluble fibrils that accumulate in AD plaques. Recent data indicate that small soluble oligomeric forms, as short as dimers, are the main neurotoxic species involved in the pathogenesis of AD (<xref ref-type="bibr" rid="B17">17</xref>, <xref ref-type="bibr" rid="B18">18</xref>). Our current findings indicate that neuroprotection may be achieved by shifting the equilibria of A&#x003b2; accumulation away from the potentially more hazardous oligomeric species, such as by BChE. In cross-linking and electron microscopy experiments, BSP peptides affected A&#x003b2; assembly less efficiently than rBChE-U. Also, BSP-K displayed less effective attenuation than BSP-U, possibly because it interacted with the A&#x003b2; monomers and/or intermediates less tightly. The differences in interactions are likely to be involved in the rBChE-U protection from A&#x003b2; neurotoxicity in cultured cells, where the peptides failed to provide protection.</p><p>The specific association between A&#x003b2; and the cell membrane has been shown to be the initial step in the chain of events that leads to toxicity (<xref ref-type="bibr" rid="B54">54</xref>). Our findings demonstrate that rBChE-U interacts with the neurotoxic A&#x003b2; oligomers, whereas A&#x003b2;-BSP interactions are much less effective. This is compatible with the hypothesis that BChE-U blocks the association of A&#x003b2; oligomers with the cell membrane. Therefore, BSP peptides are essential but are unable to promote such protection on their own. Furthermore, we demonstrated that the rBChE-U disruption extended to active fibril disassembly, compatible with a mechanism suggested by others (<xref ref-type="bibr" rid="B55">55</xref>), whereby inhibitor binding to the edge of the fibril leads to disassembly of the fibril by gradual strand removal. However, this mechanism requires high ratios of inhibitor to A&#x003b2; and therefore does not fit the 1:100 ratio we observed, in which a single rBChE-U molecule can initiate breakdown of large A&#x003b2; oligomers. Rather, our results suggest that the symmetry between the layers is broken by steric hindrance, which induces structural instabilities due to the Ala to Thr mutation and leads to collapse of the entire structure of the fibril. The same structural features that destabilize BChE-K are therefore those that make it less effective as a neuroprotector.</p></sec><sec sec-type="supplementary-material"><title>Supplementary Material</title><supplementary-material id="PMC_1" content-type="local-data"><caption><title>[Author Profile]</title></caption><media mimetype="text" mime-subtype="html" xlink:href="supp_284_25_17170__index.html"/><media xlink:role="associated-file" mimetype="application" mime-subtype="pdf" xlink:href="supp_284_25_17170__1.pdf"/></supplementary-material></sec></body><back><fn-group><fn id="FN1" fn-type="supported-by"><label>*</label><p>This work was supported by a grant from the Hurwitz Fund (to H. S.).</p></fn><fn id="FN2" fn-type="supplementary-material"><p><sup><inline-graphic xlink:href="sbox.jpg"/></sup> The on-line version of this article (available at <ext-link ext-link-type="uri" xlink:href="http://www.jbc.org">http://www.jbc.org</ext-link>) contains two <ext-link ext-link-type="uri" xlink:href="http://www.jbc.org/cgi/content/full/M109.004952/DC1">supplemental tables</ext-link> and four <ext-link ext-link-type="uri" xlink:href="http://www.jbc.org/cgi/content/full/M109.004952/DC1">supplemental figures</ext-link>.</p></fn><fn fn-type="other" id="FN6"><label>4</label><p> T. D. Goddard and D. G. Kueller, University of California, San Francisco, CA, personal communication.</p></fn></fn-group><fn-group content-type="abbreviations"><fn id="FN5"><label>3</label><p>The abbreviations used are: <def-list><def-item><term id="G1">BChE</term><def><p>butyrylcholinesterase</p></def></def-item><def-item><term id="G2">BChE-K</term><def><p>Kalow variant of BChE</p></def></def-item><def-item><term id="G3">BChE-U</term><def><p>usual BChE</p></def></def-item><def-item><term id="G4">rBChE-U</term><def><p>recombinant rBChE-U</p></def></def-item><def-item><term id="G5">BSP</term><def><p>BChE-derived synthetic peptide</p></def></def-item><def-item><term id="G6">ACh</term><def><p>acetylcholine</p></def></def-item><def-item><term id="G7">AChE</term><def><p>acetylcholinesterase</p></def></def-item><def-item><term id="G8">AChE-S</term><def><p>synaptic AChE</p></def></def-item><def-item><term id="G9">ATCh</term><def><p>acetylthiocholine</p></def></def-item><def-item><term id="G10">AD</term><def><p>Alzheimer disease</p></def></def-item><def-item><term id="G11">A&#x003b2;</term><def><p>&#x003b2;-amyloid</p></def></def-item><def-item><term id="G12">polyP</term><def><p>poly-<sc>l</sc>-proline</p></def></def-item><def-item><term id="G13">bis-ANS</term><def><p>4,4&#x02032;-dianilino-1,1&#x02032;-binaphthyl-5,5&#x02032;-sulfonate</p></def></def-item><def-item><term id="G14">TTR</term><def><p>Transthyretin</p></def></def-item><def-item><term id="G15">LDH</term><def><p>lactate dehydrogenase</p></def></def-item><def-item><term id="G16">TEM</term><def><p>transmission electron microscopy</p></def></def-item><def-item><term id="G17">ThT</term><def><p>thioflavin T</p></def></def-item><def-item><term id="G18">Tricine</term><def><p><italic>N</italic>-[2-hydroxy-1,1-bis(hydroxymethyl)ethyl]glycine</p></def></def-item><def-item><term id="G19">DMSO</term><def><p>dimethyl sulfoxide.</p></def></def-item></def-list></p></fn></fn-group><ack><title>Acknowledgments</title><p>We are grateful to Dr. Tsafrir Bravman and Monica Dines (Bio-Rad, Haifa, Israel) for collaborative efforts.</p></ack><ref-list><title>REFERENCES</title><ref id="B1"><label>1.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>G&#x000f3;mez-Ramos</surname><given-names>P.</given-names></name><name><surname>Mor&#x000e1;n</surname><given-names>M. A.</given-names></name></person-group> (<year>1997</year>) <source>Mol. Chem. Neuropathol.</source><volume>30</volume>, <fpage>161</fpage>&#x02013;<lpage>173</lpage><pub-id pub-id-type="pmid">9165483</pub-id></mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carson</surname><given-names>K. A.</given-names></name><name><surname>Geula</surname><given-names>C.</given-names></name><name><surname>Mesulam</surname><given-names>M. M.</given-names></name></person-group> (<year>1991</year>) <source>Brain Res.</source><volume>540</volume>, <fpage>204</fpage>&#x02013;<lpage>208</lpage><pub-id pub-id-type="pmid">2054612</pub-id></mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guillozet</surname><given-names>A. L.</given-names></name><name><surname>Smiley</surname><given-names>J. F.</given-names></name><name><surname>Mash</surname><given-names>D. C.</given-names></name><name><surname>Mesulam</surname><given-names>M. M.</given-names></name></person-group> (<year>1997</year>) <source>Ann. Neurol.</source><volume>42</volume>, <fpage>909</fpage>&#x02013;<lpage>918</lpage><pub-id pub-id-type="pmid">9403484</pub-id></mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Perry</surname><given-names>E. K.</given-names></name><name><surname>Perry</surname><given-names>R. H.</given-names></name><name><surname>Blessed</surname><given-names>G.</given-names></name><name><surname>Tomlinson</surname><given-names>B. E.</given-names></name></person-group> (<year>1978</year>) <source>Neuropathol. Appl. Neurobiol.</source><volume>4</volume>, <fpage>273</fpage>&#x02013;<lpage>277</lpage><pub-id pub-id-type="pmid">703927</pub-id></mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mor&#x000e1;n</surname><given-names>M. A.</given-names></name><name><surname>Mufson</surname><given-names>E. J.</given-names></name><name><surname>G&#x000f3;mez-Ramos</surname><given-names>P.</given-names></name></person-group> (<year>1993</year>) <source>Acta Neuropathol.</source><volume>85</volume>, <fpage>362</fpage>&#x02013;<lpage>369</lpage><pub-id pub-id-type="pmid">8480510</pub-id></mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wright</surname><given-names>C. I.</given-names></name><name><surname>Geula</surname><given-names>C.</given-names></name><name><surname>Mesulam</surname><given-names>M. M.</given-names></name></person-group> (<year>1993</year>) <source>Ann. Neurol.</source><volume>34</volume>, <fpage>373</fpage>&#x02013;<lpage>384</lpage><pub-id pub-id-type="pmid">8363355</pub-id></mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lansbury</surname><given-names>P. T.</given-names><suffix>Jr.</suffix></name></person-group> (<year>1992</year>) <source>Biochemistry</source><volume>31</volume>, <fpage>6865</fpage>&#x02013;<lpage>6870</lpage><pub-id pub-id-type="pmid">1637821</pub-id></mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lomakin</surname><given-names>A.</given-names></name><name><surname>Chung</surname><given-names>D. S.</given-names></name><name><surname>Benedek</surname><given-names>G. B.</given-names></name><name><surname>Kirschner</surname><given-names>D. A.</given-names></name><name><surname>Teplow</surname><given-names>D. B.</given-names></name></person-group> (<year>1996</year>) <source>Proc. Natl. Acad. Sci. U. S. A.</source><volume>93</volume>, <fpage>1125</fpage>&#x02013;<lpage>1129</lpage><pub-id pub-id-type="pmid">8577726</pub-id></mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shen</surname><given-names>J.</given-names></name><name><surname>Kelleher</surname><given-names>R. J.</given-names><suffix>3rd</suffix></name></person-group> (<year>2007</year>) <source>Proc. Natl. Acad. Sci. U. S. A.</source><volume>104</volume>, <fpage>403</fpage>&#x02013;<lpage>409</lpage><pub-id pub-id-type="pmid">17197420</pub-id></mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pratic&#x000f3;</surname><given-names>D.</given-names></name></person-group> (<year>2008</year>) <source>Ann. N.Y. Acad. Sci.</source><volume>1147</volume>, <fpage>70</fpage>&#x02013;<lpage>78</lpage><pub-id pub-id-type="pmid">19076432</pub-id></mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bush</surname><given-names>A. I.</given-names></name><name><surname>Tanzi</surname><given-names>R. E.</given-names></name></person-group> (<year>2008</year>) <source>Neurotherapeutics</source><volume>5</volume>, <fpage>421</fpage>&#x02013;<lpage>432</lpage><pub-id pub-id-type="pmid">18625454</pub-id></mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhu</surname><given-names>X.</given-names></name><name><surname>Raina</surname><given-names>A. K.</given-names></name><name><surname>Perry</surname><given-names>G.</given-names></name><name><surname>Smith</surname><given-names>M. A.</given-names></name></person-group> (<year>2004</year>) <source>Lancet Neurol.</source><volume>3</volume>, <fpage>219</fpage>&#x02013;<lpage>226</lpage><pub-id pub-id-type="pmid">15039034</pub-id></mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mancuso</surname><given-names>M.</given-names></name><name><surname>Copped&#x000e8;</surname><given-names>F.</given-names></name><name><surname>Murri</surname><given-names>L.</given-names></name><name><surname>Siciliano</surname><given-names>G.</given-names></name></person-group> (<year>2007</year>) <source>Antioxid. Redox Signal.</source><volume>9</volume>, <fpage>1631</fpage>&#x02013;<lpage>1646</lpage><pub-id pub-id-type="pmid">17887917</pub-id></mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>H. G.</given-names></name><name><surname>Casadesus</surname><given-names>G.</given-names></name><name><surname>Zhu</surname><given-names>X.</given-names></name><name><surname>Takeda</surname><given-names>A.</given-names></name><name><surname>Perry</surname><given-names>G.</given-names></name><name><surname>Smith</surname><given-names>M. A.</given-names></name></person-group> (<year>2004</year>) <source>Ann. N.Y. Acad. Sci.</source><volume>1019</volume>, <fpage>1</fpage>&#x02013;<lpage>4</lpage><pub-id pub-id-type="pmid">15246983</pub-id></mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hardy</surname><given-names>J.</given-names></name><name><surname>Selkoe</surname><given-names>D. J.</given-names></name></person-group> (<year>2002</year>) <source>Science</source><volume>297</volume>, <fpage>353</fpage>&#x02013;<lpage>356</lpage><pub-id pub-id-type="pmid">12130773</pub-id></mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Altamirano</surname><given-names>C. V.</given-names></name><name><surname>Lockridge</surname><given-names>O.</given-names></name></person-group> (<year>1999</year>) <source>Chem. Biol. Interact.</source><volume>119&#x02013;120</volume>, <fpage>53</fpage>&#x02013;<lpage>60</lpage></mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blong</surname><given-names>R. M.</given-names></name><name><surname>Bedows</surname><given-names>E.</given-names></name><name><surname>Lockridge</surname><given-names>O.</given-names></name></person-group> (<year>1997</year>) <source>Biochem. J.</source><volume>327</volume>, <fpage>747</fpage>&#x02013;<lpage>757</lpage><pub-id pub-id-type="pmid">9581552</pub-id></mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Perrier</surname><given-names>A. L.</given-names></name><name><surname>Massouli&#x000e9;</surname><given-names>J.</given-names></name><name><surname>Krejci</surname><given-names>E.</given-names></name></person-group> (<year>2002</year>) <source>Neuron</source><volume>33</volume>, <fpage>275</fpage>&#x02013;<lpage>285</lpage><pub-id pub-id-type="pmid">11804574</pub-id></mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bon</surname><given-names>S.</given-names></name><name><surname>Ayon</surname><given-names>A.</given-names></name><name><surname>Leroy</surname><given-names>J.</given-names></name><name><surname>Massouli&#x000e9;</surname><given-names>J.</given-names></name></person-group> (<year>2003</year>) <source>Neurochem. Res.</source><volume>28</volume>, <fpage>523</fpage>&#x02013;<lpage>535</lpage><pub-id pub-id-type="pmid">12675141</pub-id></mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>H.</given-names></name><name><surname>Schopfer</surname><given-names>L. M.</given-names></name><name><surname>Masson</surname><given-names>P.</given-names></name><name><surname>Lockridge</surname><given-names>O.</given-names></name></person-group> (<year>2008</year>) <source>Biochem. J.</source><volume>411</volume>, <fpage>425</fpage>&#x02013;<lpage>432</lpage><pub-id pub-id-type="pmid">18076380</pub-id></mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nicolet</surname><given-names>Y.</given-names></name><name><surname>Lockridge</surname><given-names>O.</given-names></name><name><surname>Masson</surname><given-names>P.</given-names></name><name><surname>Fontecilla-Camps</surname><given-names>J. C.</given-names></name><name><surname>Nachon</surname><given-names>F.</given-names></name></person-group> (<year>2003</year>) <source>J. Biol. Chem.</source><volume>278</volume>, <fpage>41141</fpage>&#x02013;<lpage>41147</lpage><pub-id pub-id-type="pmid">12869558</pub-id></mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ngamelue</surname><given-names>M. N.</given-names></name><name><surname>Homma</surname><given-names>K.</given-names></name><name><surname>Lockridge</surname><given-names>O.</given-names></name><name><surname>Asojo</surname><given-names>O. A.</given-names></name></person-group> (<year>2007</year>) <source>Acta Crystallogr. F Struct. Biol. Cryst. Commun.</source><volume>63</volume>, <fpage>723</fpage>&#x02013;<lpage>727</lpage></mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dvir</surname><given-names>H.</given-names></name><name><surname>Harel</surname><given-names>M.</given-names></name><name><surname>Bon</surname><given-names>S.</given-names></name><name><surname>Liu</surname><given-names>W. Q.</given-names></name><name><surname>Vidal</surname><given-names>M.</given-names></name><name><surname>Garbay</surname><given-names>C.</given-names></name><name><surname>Sussman</surname><given-names>J. L.</given-names></name><name><surname>Massouli&#x000e9;</surname><given-names>J.</given-names></name><name><surname>Silman</surname><given-names>I.</given-names></name></person-group> (<year>2004</year>) <source>EMBO J.</source><volume>23</volume>, <fpage>4394</fpage>&#x02013;<lpage>4405</lpage><pub-id pub-id-type="pmid">15526038</pub-id></mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bartels</surname><given-names>C. F.</given-names></name><name><surname>Jensen</surname><given-names>F. S.</given-names></name><name><surname>Lockridge</surname><given-names>O.</given-names></name><name><surname>van der Spek</surname><given-names>A. F.</given-names></name><name><surname>Rubinstein</surname><given-names>H. M.</given-names></name><name><surname>Lubrano</surname><given-names>T.</given-names></name><name><surname>La Du</surname><given-names>B. N.</given-names></name></person-group> (<year>1992</year>) <source>Am. J. Hum. Genet.</source><volume>50</volume>, <fpage>1086</fpage>&#x02013;<lpage>1103</lpage><pub-id pub-id-type="pmid">1570838</pub-id></mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Diamant</surname><given-names>S.</given-names></name><name><surname>Podoly</surname><given-names>E.</given-names></name><name><surname>Friedler</surname><given-names>A.</given-names></name><name><surname>Ligumsky</surname><given-names>H.</given-names></name><name><surname>Livnah</surname><given-names>O.</given-names></name><name><surname>Soreq</surname><given-names>H.</given-names></name></person-group> (<year>2006</year>) <source>Proc. Natl. Acad. Sci. U. S. A.</source><volume>103</volume>, <fpage>8628</fpage>&#x02013;<lpage>8633</lpage><pub-id pub-id-type="pmid">16731619</pub-id></mixed-citation></ref><ref id="B26"><label>26.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baden</surname><given-names>E. M.</given-names></name><name><surname>Owen</surname><given-names>B. A.</given-names></name><name><surname>Peterson</surname><given-names>F. C.</given-names></name><name><surname>Volkman</surname><given-names>B. F.</given-names></name><name><surname>Ramirez-Alvarado</surname><given-names>M.</given-names></name><name><surname>Thompson</surname><given-names>J. R.</given-names></name></person-group> (<year>2008</year>) <source>J. Biol. Chem.</source><volume>283</volume>, <fpage>15853</fpage>&#x02013;<lpage>15860</lpage><pub-id pub-id-type="pmid">18400753</pub-id></mixed-citation></ref><ref id="B27"><label>27.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hurshman Babbes</surname><given-names>A. R.</given-names></name><name><surname>Powers</surname><given-names>E. T.</given-names></name><name><surname>Kelly</surname><given-names>J. W.</given-names></name></person-group> (<year>2008</year>) <source>Biochemistry</source><volume>47</volume>, <fpage>6969</fpage>&#x02013;<lpage>6984</lpage><pub-id pub-id-type="pmid">18537267</pub-id></mixed-citation></ref><ref id="B28"><label>28.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>O'Brien</surname><given-names>K. K.</given-names></name><name><surname>Saxby</surname><given-names>B. K.</given-names></name><name><surname>Ballard</surname><given-names>C. G.</given-names></name><name><surname>Grace</surname><given-names>J.</given-names></name><name><surname>Harrington</surname><given-names>F.</given-names></name><name><surname>Ford</surname><given-names>G. A.</given-names></name><name><surname>O'Brien</surname><given-names>J. T.</given-names></name><name><surname>Swan</surname><given-names>A. G.</given-names></name><name><surname>Fairbairn</surname><given-names>A. F.</given-names></name><name><surname>Wesnes</surname><given-names>K.</given-names></name><name><surname>del Ser</surname><given-names>T.</given-names></name><name><surname>Edwardson</surname><given-names>J. A.</given-names></name><name><surname>Morris</surname><given-names>C. M.</given-names></name><name><surname>McKeith</surname><given-names>I. G.</given-names></name></person-group> (<year>2003</year>) <source>Pharmacogenetics</source><volume>13</volume>, <fpage>231</fpage>&#x02013;<lpage>239</lpage><pub-id pub-id-type="pmid">12668920</pub-id></mixed-citation></ref><ref id="B29"><label>29.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lopez</surname><given-names>O. L.</given-names></name><name><surname>Becker</surname><given-names>J. T.</given-names></name><name><surname>Wisniewski</surname><given-names>S.</given-names></name><name><surname>Saxton</surname><given-names>J.</given-names></name><name><surname>Kaufer</surname><given-names>D. I.</given-names></name><name><surname>DeKosky</surname><given-names>S. T.</given-names></name></person-group> (<year>2002</year>) <source>J. Neurol. Neurosurg. Psychiatry</source><volume>72</volume>, <fpage>310</fpage>&#x02013;<lpage>314</lpage><pub-id pub-id-type="pmid">11861686</pub-id></mixed-citation></ref><ref id="B30"><label>30.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ghebremedhin</surname><given-names>E.</given-names></name><name><surname>Thal</surname><given-names>D. R.</given-names></name><name><surname>Schultz</surname><given-names>C.</given-names></name><name><surname>Braak</surname><given-names>H.</given-names></name></person-group> (<year>2002</year>) <source>Neurosci. Lett.</source><volume>320</volume>, <fpage>25</fpage>&#x02013;<lpage>28</lpage><pub-id pub-id-type="pmid">11849755</pub-id></mixed-citation></ref><ref id="B31"><label>31.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Holmes</surname><given-names>C.</given-names></name><name><surname>Ballard</surname><given-names>C.</given-names></name><name><surname>Lehmann</surname><given-names>D.</given-names></name><name><surname>David Smith</surname><given-names>A.</given-names></name><name><surname>Beaumont</surname><given-names>H.</given-names></name><name><surname>Day</surname><given-names>I. N.</given-names></name><name><surname>Nadeem Khan</surname><given-names>M.</given-names></name><name><surname>Lovestone</surname><given-names>S.</given-names></name><name><surname>McCulley</surname><given-names>M.</given-names></name><name><surname>Morris</surname><given-names>C. M.</given-names></name><name><surname>Munoz</surname><given-names>D. G.</given-names></name><name><surname>O'Brien</surname><given-names>K.</given-names></name><name><surname>Russ</surname><given-names>C.</given-names></name><name><surname>Del Ser</surname><given-names>T.</given-names></name><name><surname>Warden</surname><given-names>D.</given-names></name></person-group> (<year>2005</year>) <source>J. Neurol. Neurosurg. Psychiatry</source><volume>76</volume>, <fpage>640</fpage>&#x02013;<lpage>643</lpage><pub-id pub-id-type="pmid">15834019</pub-id></mixed-citation></ref><ref id="B32"><label>32.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bertram</surname><given-names>L.</given-names></name><name><surname>McQueen</surname><given-names>M. B.</given-names></name><name><surname>Mullin</surname><given-names>K.</given-names></name><name><surname>Blacker</surname><given-names>D.</given-names></name><name><surname>Tanzi</surname><given-names>R. E.</given-names></name></person-group> (<year>2007</year>) <source>Nat. Genet.</source><volume>39</volume>, <fpage>17</fpage>&#x02013;<lpage>23</lpage><pub-id pub-id-type="pmid">17192785</pub-id></mixed-citation></ref><ref id="B33"><label>33.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arendt</surname><given-names>T.</given-names></name><name><surname>Br&#x000fc;ckner</surname><given-names>M. K.</given-names></name><name><surname>Lange</surname><given-names>M.</given-names></name><name><surname>Bigl</surname><given-names>V.</given-names></name></person-group> (<year>1992</year>) <source>Neurochem. Int.</source><volume>21</volume>, <fpage>381</fpage>&#x02013;<lpage>396</lpage><pub-id pub-id-type="pmid">1303164</pub-id></mixed-citation></ref><ref id="B34"><label>34.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ben Assayag</surname><given-names>E.</given-names></name><name><surname>Bova</surname><given-names>I.</given-names></name><name><surname>Berliner</surname><given-names>S.</given-names></name><name><surname>Peretz</surname><given-names>H.</given-names></name><name><surname>Usher</surname><given-names>S.</given-names></name><name><surname>Shapira</surname><given-names>I.</given-names></name><name><surname>Bornstein</surname><given-names>N. M.</given-names></name></person-group> (<year>2006</year>) <source>Thromb. Haemost.</source><volume>95</volume>, <fpage>428</fpage>&#x02013;<lpage>433</lpage><pub-id pub-id-type="pmid">16525569</pub-id></mixed-citation></ref><ref id="B35"><label>35.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>G&#x000e4;tke</surname><given-names>M. R.</given-names></name><name><surname>Viby-Mogensen</surname><given-names>J.</given-names></name><name><surname>Bundgaard</surname><given-names>J. R.</given-names></name></person-group> (<year>2002</year>) <source>Scand. J. Clin. Lab. Invest.</source><volume>62</volume>, <fpage>375</fpage>&#x02013;<lpage>383</lpage><pub-id pub-id-type="pmid">12387584</pub-id></mixed-citation></ref><ref id="B36"><label>36.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ofek</surname><given-names>K.</given-names></name><name><surname>Krabbe</surname><given-names>K. S.</given-names></name><name><surname>Evron</surname><given-names>T.</given-names></name><name><surname>Debecco</surname><given-names>M.</given-names></name><name><surname>Nielsen</surname><given-names>A. R.</given-names></name><name><surname>Brunnsgaad</surname><given-names>H.</given-names></name><name><surname>Yirmiya</surname><given-names>R.</given-names></name><name><surname>Soreq</surname><given-names>H.</given-names></name><name><surname>Pedersen</surname><given-names>B. K.</given-names></name></person-group> (<year>2007</year>) <source>J. Mol. Med.</source><volume>85</volume>, <fpage>1239</fpage>&#x02013;<lpage>1251</lpage><pub-id pub-id-type="pmid">17657467</pub-id></mixed-citation></ref><ref id="B37"><label>37.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Karnovsky</surname><given-names>M. J.</given-names></name><name><surname>Roots</surname><given-names>L.</given-names></name></person-group> (<year>1964</year>) <source>J. Histochem. Cytochem.</source><volume>12</volume>, <fpage>219</fpage>&#x02013;<lpage>221</lpage><pub-id pub-id-type="pmid">14187330</pub-id></mixed-citation></ref><ref id="B38"><label>38.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Berson</surname><given-names>A.</given-names></name><name><surname>Knobloch</surname><given-names>M.</given-names></name><name><surname>Hanan</surname><given-names>M.</given-names></name><name><surname>Diamant</surname><given-names>S.</given-names></name><name><surname>Sharoni</surname><given-names>M.</given-names></name><name><surname>Schuppli</surname><given-names>D.</given-names></name><name><surname>Geyer</surname><given-names>B. C.</given-names></name><name><surname>Ravid</surname><given-names>R.</given-names></name><name><surname>Mor</surname><given-names>T. S.</given-names></name><name><surname>Nitsch</surname><given-names>R. M.</given-names></name><name><surname>Soreq</surname><given-names>H.</given-names></name></person-group> (<year>2008</year>) <source>Brain</source><volume>131</volume>, <fpage>109</fpage>&#x02013;<lpage>119</lpage><pub-id pub-id-type="pmid">18056160</pub-id></mixed-citation></ref><ref id="B39"><label>39.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Piotto</surname><given-names>M.</given-names></name><name><surname>Saudek</surname><given-names>V.</given-names></name><name><surname>Sklen&#x000e1;r</surname><given-names>V.</given-names></name></person-group> (<year>1992</year>) <source>J. Biomol. NMR</source><volume>2</volume>, <fpage>661</fpage>&#x02013;<lpage>665</lpage><pub-id pub-id-type="pmid">1490109</pub-id></mixed-citation></ref><ref id="B40"><label>40.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wagner</surname><given-names>R.</given-names></name><name><surname>Berger</surname><given-names>S.</given-names></name></person-group> (<year>1996</year>) <source>J. Magn. Reson. A</source><volume>123</volume>, <fpage>119</fpage>&#x02013;<lpage>121</lpage><pub-id pub-id-type="pmid">8980072</pub-id></mixed-citation></ref><ref id="B41"><label>41.</label><mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>W&#x000fc;thrich</surname><given-names>K.</given-names></name></person-group> (<year>1986</year>) <source>NMR of Proteins and Nucleic Acids</source> , <publisher-name>John Wiley &#x00026; Sons</publisher-name>, <publisher-loc>New York</publisher-loc></mixed-citation></ref><ref id="B42"><label>42.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fancy</surname><given-names>D. A.</given-names></name><name><surname>Kodadek</surname><given-names>T.</given-names></name></person-group> (<year>1999</year>) <source>Proc. Natl. Acad. Sci. U. S. A.</source><volume>96</volume>, <fpage>6020</fpage>&#x02013;<lpage>6024</lpage><pub-id pub-id-type="pmid">10339534</pub-id></mixed-citation></ref><ref id="B43"><label>43.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Podoly</surname><given-names>E.</given-names></name><name><surname>Bruck</surname><given-names>T.</given-names></name><name><surname>Diamant</surname><given-names>S.</given-names></name><name><surname>Melamed-Book</surname><given-names>N.</given-names></name><name><surname>Weiss</surname><given-names>A.</given-names></name><name><surname>Huang</surname><given-names>Y.</given-names></name><name><surname>Livnah</surname><given-names>O.</given-names></name><name><surname>Langermann</surname><given-names>S.</given-names></name><name><surname>Wilgus</surname><given-names>H.</given-names></name><name><surname>Soreq</surname><given-names>H.</given-names></name></person-group> (<year>2008</year>) <source>Neurodegener. Dis.</source><volume>5</volume>, <fpage>232</fpage>&#x02013;<lpage>236</lpage><pub-id pub-id-type="pmid">18322399</pub-id></mixed-citation></ref><ref id="B44"><label>44.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Whitmore</surname><given-names>L.</given-names></name><name><surname>Wallace</surname><given-names>B. A.</given-names></name></person-group> (<year>2004</year>) <source>Nucleic Acids Res.</source><volume>32</volume>, <fpage>W668</fpage>&#x02013;<lpage>673</lpage><pub-id pub-id-type="pmid">15215473</pub-id></mixed-citation></ref><ref id="B45"><label>45.</label><mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Bergmeyer</surname><given-names>H. U.</given-names></name><name><surname>Bernt</surname><given-names>E.</given-names></name><name><surname>Hess</surname><given-names>B.</given-names></name></person-group> (<year>1963</year>) in <source>Methods of Enzymatic Analysis</source> ( <person-group person-group-type="editor"><name><surname>Bergmeyer</surname><given-names>H. U.</given-names></name></person-group> ed), pp. <fpage>736</fpage>&#x02013;<lpage>743</lpage>, <publisher-name>Academic Press</publisher-name>, <publisher-loc>New York, NY</publisher-loc></mixed-citation></ref><ref id="B46"><label>46.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>Y. J.</given-names></name><name><surname>Huang</surname><given-names>Y.</given-names></name><name><surname>Baldassarre</surname><given-names>H.</given-names></name><name><surname>Wang</surname><given-names>B.</given-names></name><name><surname>Lazaris</surname><given-names>A.</given-names></name><name><surname>Leduc</surname><given-names>M.</given-names></name><name><surname>Bilodeau</surname><given-names>A. S.</given-names></name><name><surname>Bellemare</surname><given-names>A.</given-names></name><name><surname>C&#x000f4;t&#x000e9;</surname><given-names>M.</given-names></name><name><surname>Herskovits</surname><given-names>P.</given-names></name><name><surname>Touati</surname><given-names>M.</given-names></name><name><surname>Turcotte</surname><given-names>C.</given-names></name><name><surname>Valeanu</surname><given-names>L.</given-names></name><name><surname>Lem&#x000e9;e</surname><given-names>N.</given-names></name><name><surname>Wilgus</surname><given-names>H.</given-names></name><name><surname>B&#x000e9;gin</surname><given-names>I.</given-names></name><name><surname>Bhatia</surname><given-names>B.</given-names></name><name><surname>Rao</surname><given-names>K.</given-names></name><name><surname>Neveu</surname><given-names>N.</given-names></name><name><surname>Brochu</surname><given-names>E.</given-names></name><name><surname>Pierson</surname><given-names>J.</given-names></name><name><surname>Hockley</surname><given-names>D. K.</given-names></name><name><surname>Cerasoli</surname><given-names>D. M.</given-names></name><name><surname>Lenz</surname><given-names>D. E.</given-names></name><name><surname>Karatzas</surname><given-names>C. N.</given-names></name><name><surname>Langermann</surname><given-names>S.</given-names></name></person-group> (<year>2007</year>) <source>Proc. Natl. Acad. Sci. U. S. A.</source><volume>104</volume>, <fpage>13603</fpage>&#x02013;<lpage>13608</lpage><pub-id pub-id-type="pmid">17660298</pub-id></mixed-citation></ref><ref id="B47"><label>47.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dahlgren</surname><given-names>K. N.</given-names></name><name><surname>Manelli</surname><given-names>A. M.</given-names></name><name><surname>Stine</surname><given-names>W. B.</given-names><suffix>Jr.</suffix></name><name><surname>Baker</surname><given-names>L. K.</given-names></name><name><surname>Krafft</surname><given-names>G. A.</given-names></name><name><surname>LaDu</surname><given-names>M. J.</given-names></name></person-group> (<year>2002</year>) <source>J. Biol. Chem.</source><volume>277</volume>, <fpage>32046</fpage>&#x02013;<lpage>32053</lpage><pub-id pub-id-type="pmid">12058030</pub-id></mixed-citation></ref><ref id="B48"><label>48.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Klein</surname><given-names>W. L.</given-names></name><name><surname>Stine</surname><given-names>W. B.</given-names><suffix>Jr.</suffix></name><name><surname>Teplow</surname><given-names>D. B.</given-names></name></person-group> (<year>2004</year>) <source>Neurobiol. Aging</source><volume>25</volume>, <fpage>569</fpage>&#x02013;<lpage>580</lpage><pub-id pub-id-type="pmid">15172732</pub-id></mixed-citation></ref><ref id="B49"><label>49.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Edwards</surname><given-names>J. A.</given-names></name><name><surname>Brimijoin</surname><given-names>S.</given-names></name></person-group> (<year>1983</year>) <source>Biochim. Biophys. Acta</source><volume>742</volume>, <fpage>509</fpage>&#x02013;<lpage>516</lpage><pub-id pub-id-type="pmid">6838885</pub-id></mixed-citation></ref><ref id="B50"><label>50.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tidow</surname><given-names>H.</given-names></name><name><surname>Melero</surname><given-names>R.</given-names></name><name><surname>Mylonas</surname><given-names>E.</given-names></name><name><surname>Freund</surname><given-names>S. M.</given-names></name><name><surname>Grossmann</surname><given-names>J. G.</given-names></name><name><surname>Carazo</surname><given-names>J. M.</given-names></name><name><surname>Svergun</surname><given-names>D. I.</given-names></name><name><surname>Valle</surname><given-names>M.</given-names></name><name><surname>Fersht</surname><given-names>A. R.</given-names></name></person-group> (<year>2007</year>) <source>Proc. Natl. Acad. Sci. U. S. A.</source><volume>104</volume>, <fpage>12324</fpage>&#x02013;<lpage>12329</lpage><pub-id pub-id-type="pmid">17620598</pub-id></mixed-citation></ref><ref id="B51"><label>51.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chou</surname><given-names>P. Y.</given-names></name><name><surname>Fasman</surname><given-names>G. D.</given-names></name></person-group> (<year>1974</year>) <source>Biochemistry</source><volume>13</volume>, <fpage>211</fpage>&#x02013;<lpage>222</lpage><pub-id pub-id-type="pmid">4358939</pub-id></mixed-citation></ref><ref id="B52"><label>52.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heise</surname><given-names>H.</given-names></name><name><surname>Celej</surname><given-names>M. S.</given-names></name><name><surname>Becker</surname><given-names>S.</given-names></name><name><surname>Riedel</surname><given-names>D.</given-names></name><name><surname>Pelah</surname><given-names>A.</given-names></name><name><surname>Kumar</surname><given-names>A.</given-names></name><name><surname>Jovin</surname><given-names>T. M.</given-names></name><name><surname>Baldus</surname><given-names>M.</given-names></name></person-group> (<year>2008</year>) <source>J. Mol. Biol.</source><volume>380</volume>, <fpage>444</fpage>&#x02013;<lpage>450</lpage><pub-id pub-id-type="pmid">18539297</pub-id></mixed-citation></ref><ref id="B53"><label>53.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Glabe</surname><given-names>C.</given-names></name></person-group> (<year>2001</year>) <source>J. Mol. Neurosci.</source><volume>17</volume>, <fpage>137</fpage>&#x02013;<lpage>145</lpage><pub-id pub-id-type="pmid">11816787</pub-id></mixed-citation></ref><ref id="B54"><label>54.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Demuro</surname><given-names>A.</given-names></name><name><surname>Mina</surname><given-names>E.</given-names></name><name><surname>Kayed</surname><given-names>R.</given-names></name><name><surname>Milton</surname><given-names>S. C.</given-names></name><name><surname>Parker</surname><given-names>I.</given-names></name><name><surname>Glabe</surname><given-names>C. G.</given-names></name></person-group> (<year>2005</year>) <source>J. Biol. Chem.</source><volume>280</volume>, <fpage>17294</fpage>&#x02013;<lpage>17300</lpage><pub-id pub-id-type="pmid">15722360</pub-id></mixed-citation></ref><ref id="B55"><label>55.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Soto</surname><given-names>P.</given-names></name><name><surname>Griffin</surname><given-names>M. A.</given-names></name><name><surname>Shea</surname><given-names>J. E.</given-names></name></person-group> (<year>2007</year>) <source>Biophys. J.</source><volume>93</volume>, <fpage>3015</fpage>&#x02013;<lpage>3025</lpage><pub-id pub-id-type="pmid">17631541</pub-id></mixed-citation></ref><ref id="B56"><label>56.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arpagaus</surname><given-names>M.</given-names></name><name><surname>Kott</surname><given-names>M.</given-names></name><name><surname>Vatsis</surname><given-names>K. P.</given-names></name><name><surname>Bartels</surname><given-names>C. F.</given-names></name><name><surname>La Du</surname><given-names>B. N.</given-names></name><name><surname>Lockridge</surname><given-names>O.</given-names></name></person-group> (<year>1990</year>) <source>Biochemistry</source><volume>29</volume>, <fpage>124</fpage>&#x02013;<lpage>131</lpage><pub-id pub-id-type="pmid">2322535</pub-id></mixed-citation></ref></ref-list></back></article>